Shots:
- The CHMP has recommended Libtayo (cemiplimab) as an adj. treatment for CSCC adults who are at high risk for recurrence after surgery & radiation
- Opinion was based on the P-III (C-POST) trial assessing Libtayo adj. (350mg, IV, Q3W for first 12wks. followed by 700mg, IV, Q6W for 36wks.; n=209) vs PBO (n=206) to treat high-risk CSCC pts (N=415) for ~48wks.
- Trial met its 1EP with a 68% reduction in disease recurrence & death risk, plus showed that 4% vs 17% & 5% vs 13% pts had locoregional or distant recurrence, respectively; data was published in The NEJM
Ref: Regeneron | Image: Regeneron | Press Release
Related News:- Regeneron Reports the US FDA’s Approval of Adjuvant Libtayo to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
